OS Cancer Research Results

OS, overall survival: Click to Expand ⟱
Source:
Type:
Overall survival

Scientific Papers found: Click to Expand⟱
5119- JG,    Juglone Suppresses Inflammation and Oxidative Stress in Colitis Mice
- in-vivo, Nor, NA
*antiOx↑, *OS↑, *IL6↓, *IL12↓, *IL23↓, *TNF-α↓, *Inflam↓, *NF-kB↓, *NFE2L2↓, *ROS↓,
1708- Lyco,    The Anti-Cancer Activity of Lycopene: A Systematic Review of Human and Animal Studies
- Review, Var, NA
OS↑, ChemoSen↑, QoL↑, PSA∅, eff↑, AntiCan↑, AntiCan↑, angioG↓, VEGF↓, Hif1a↓, SOD↑, Catalase↑, GPx↑, GSH↑, GPx↑, GR↑, MDA↓, NRF2↑, HO-1↑, COX2↓, PGE2↓, NF-kB↓, IL4↑, IL10↑, IL6↓, TNF-α↓, PPARγ↑, TumCCA↑, FOXO3↓, Casp3↑, IGF-1↓, p27↑, STAT3↓, CDK2↓, CDK4↓, P21↑, PCNA↓, MMP7↓, MMP9↓,
2500- meben,    Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme
- in-vitro, GBM, U87MG - in-vivo, GBM, NA
α-tubulin↓, AntiCan↑, TumCG↓, OS↑, VEGF↓, Hif1a↓,
1776- MEL,    Therapeutic strategies of melatonin in cancer patients: a systematic review and meta-analysis
- Review, NA, NA
Remission↑, OS↑, neuroP↑, VEGF↓, KISS1↑, TumCP↓, ChemoSideEff↓, radioP↑, Dose∅, *ROS↓, DNArepair↑, ROS↑,
1783- MEL,    The efficacy and safety of melatonin in concurrent chemotherapy or radiotherapy for solid tumors: a meta-analysis of randomized controlled trials
- Review, Var, NA
Dose∅, Remission↑, OS↑, radioP↑,
1782- MEL,    Melatonin in Cancer Treatment: Current Knowledge and Future Opportunities
- Review, Var, NA
AntiCan↑, Apoptosis↑, TumCP↓, TumCG↑, TumMeta↑, ChemoSideEff↓, radioP↑, ChemoSen↑, *ROS↓, *SOD↑, *GSH↑, *GPx↑, *Catalase↑, Dose∅, VEGF↓, eff↑, Hif1a↓, GLUT1↑, GLUT3↑, CAIX↑, P21↑, p27↑, PTEN↑, Warburg↓, PI3K↓, Akt↓, NF-kB↓, cycD1/CCND1↓, CDK4↓, CycB/CCNB1↓, CDK4↓, MAPK↑, IGF-1R↓, STAT3↓, MMP9↓, MMP2↓, MMP13↓, E-cadherin↑, Vim↓, RANKL↓, JNK↑, Bcl-2↓, P53↑, Casp3↑, Casp9↑, BAX↑, DNArepair↑, COX2↓, IL6↓, IL8↓, NO↓, T-Cell↑, NK cell↑, Treg lymp↓, FOXP3↓, CD4+↑, TNF-α↑, Th1 response↑, BioAv↝, RadioS↑, OS↑,
1781- MEL,    Melatonin in patients with cancer receiving chemotherapy: a randomized, double-blind, placebo-controlled trial
- Trial, Lung, NA
QoL↑, OS∅, selectivity↑,
1779- MEL,    Therapeutic Potential of Melatonin Counteracting Chemotherapy-Induced Toxicity in Breast Cancer Patients: A Systematic Review
- Review, BC, NA
QoL↑, OS↑, Dose∅, antiOx↑, ROS↑, SOD↑, Catalase↑, GPx↑, Risk↓, NK cell↑, IL1β↓, IL6↓, TNF-α↓, radioP↑, chemoP↑, TumVol↓, TumMeta↓, angioG↓, ChemoSen↑, eff↑,
5804- MET,  NIV,    Durable Response to Nivolumab Combined With Metformin in Advanced Pancreatic Cancer: A Case Report With Seven Years of Follow-Up.
- Case Report, PC, NA
OS↑, Dose↝,
2386- MET,    Mechanisms of metformin inhibiting cancer invasion and migration
- Review, Var, NA
OS↑, AMPK↑, EMT↓, TGF-β↓, mTOR↓, P70S6K↓, PKM2↓, Hif1a↓, ChemoSen↑,
2489- metroC,  capec,    Long-lasting response with metronomic capecitabine in advanced hepatocellular carcinoma
- Case Report, HCC, NA
Dose↝, OS↑, TumVol↓, AFP↓,
2488- metroC,    Metronomic S-1 Chemotherapy and Vandetanib: An Efficacious and Nontoxic Treatment for Hepatocellular Carcinoma
- in-vitro, HCC, HUH7 - in-vivo, HCC, NA
TumCG↓, toxicity↓, OS↑, TSP-1↑, Dose↓, Dose↓,
2486- metroC,  capec,    Sustained complete response of advanced hepatocellular carcinoma with metronomic capecitabine: a report of three cases
- Case Report, HCC, NA
OS↑, eff↝, Dose↝, AFP↓, Dose↝, TumVol↓, AFP↓,
2260- MF,    Alternative magnetic field exposure suppresses tumor growth via metabolic reprogramming
- in-vitro, GBM, U87MG - in-vitro, GBM, LN229 - in-vivo, NA, NA
TumCP↓, TumCG↓, OS↑, ROS↑, SOD2↑, eff↓, ECAR↓, OCR↑, selectivity↑, *toxicity∅, TumVol↓, PGC-1α↑, OXPHOS↑, Glycolysis↓, PKM2↓,
529- MF,    Low-frequency magnetic field therapy for glioblastoma: Current advances, mechanisms, challenges and future perspectives
- Review, GBM, NA
Ca+2↑, ROS↑, ChemoSen↑, QoL↑, OS↑,
505- MF,    Amplitude-modulated electromagnetic fields for the treatment of cancer: Discovery of tumor-specific frequencies and assessment of a novel therapeutic approach
- Case Report, NA, NA
Pain↓, OS↑,
510- MF,    Effect of a 9 mT pulsed magnetic field on C3H/Bi female mice with mammary carcinoma. A comparison between the 12 Hz and the 460 Hz frequencies
- in-vivo, NA, NA
OS↑,
5534- MF,    Targeted Osmotic Lysis of Highly Invasive Breast Carcinomas Using Pulsed Magnetic Field Stimulation of Voltage-Gated Sodium Channels and Pharmacological Blockade of Sodium Pumps
- vitro+vivo, BC, MDA-MB-231 - in-vitro, Nor, MCF10
TumVol↓, VGSC↑, OS↑, selectivity↑, eff↑,
4569- MFrot,    Case Report: A new noninvasive device-based treatment of a mesencephalic H3 K27M glioma
- Case Report, GBM, NA
Dose↝, Dose↑, Dose↑, OS↑, toxicity↓, ETC↓, ROS↑,
3499- MFrot,  MF,    Rotating magnetic field delays human umbilical vein endothelial cell aging and prolongs the lifespan of Caenorhabditis elegans
- in-vitro, Nor, HUVECs
*AntiAge↑, *AMPK↑, *mPGES-1↓, *Ca+2↑, *ER Stress↑, *OS↑, *ROS↓,
3493- MFrot,  MF,    Mechanical nanosurgery of chemoresistant glioblastoma using magnetically controlled carbon nanotubes
- in-vivo, GBM, NA
TumCD↑, MMP↓, Cyt‑c↑, Apoptosis↑, OS↑, DNAdam↑,
2259- MFrot,  MF,    Method and apparatus for oncomagnetic treatment
- in-vitro, GBM, NA
MMP↓, Bcl-2↓, BAX↑, Bak↑, Cyt‑c↑, Casp3↑, Casp9↑, DNAdam↑, ROS↑, lactateProd↑, Apoptosis↑, MPT↑, *selectivity↑, eff↑, MMP↓, selectivity↑, TCA?, H2O2↑, eff↑, *antiOx↑, H2O2↑, eff↓, GSH/GSSG↓, *toxicity∅, OS↑,
2258- MFrot,  MF,    EXTH-68. ONCOMAGNETIC TREATMENT SELECTIVELY KILLS GLIOMA CANCER CELLS BY INDUCING OXIDATIVE STRESS AND DNA DAMAGE
- in-vitro, GBM, GBM - in-vitro, Nor, SVGp12
TumVol↓, OS↑, γH2AX↑, DNAdam↑, selectivity↑, ROS↑, TumCD↑, eff↑, eff↓,
5245- MFrot,  Rad,    The hemoprotective effects of a rotary magnetic field in mice exposed to γ irradiation
- in-vivo, Nor, NA
*OS↑, *radioP↑,
5243- MFrot,    The assessment of the efficacy of the effect of a rotational magnetic field on the course of the tumor process in patients with generalized breast cancer
- Human, BC, NA
OS↑, eff↑,
190- MFrot,  MF,  Chemo,    The efficacy and safety of low-frequency rotating static magnetic field therapy combined with chemotherapy on advanced lung cancer patients: a randomized, double-blinded, controlled clinical trial
- Human, Lung, NA
*IP-10/CXCL-10↑, *GM-CSF↑, *TREM-1↓, QoL↑, Ca+2↑, ROS↑, Apoptosis↑, OS↑,
222- MFrot,  MF,    LF-MF inhibits iron metabolism and suppresses lung cancer through activation of P53-miR-34a-E2F1/E2F3 pathway
- in-vitro, Lung, A549
TumCG↓, OS↑, miR-34a↑, E2Fs↓, P53↑, TfR1/CD71↓, Ferritin↓,
224- MFrot,  MF,    A pilot study of extremely low-frequency magnetic fields in advanced non-small cell lung cancer: Effects on survival and palliation of general symptoms
- Human, NSCLC, NA
PleEff↓, breath↑, Pain↓, Appetite↑, Strength↑, BowelM↑, OS↑,
221- MFrot,  MF,    Low Frequency Magnetic Fields Enhance Antitumor Immune Response against Mouse H22 Hepatocellular Carcinoma
- in-vivo, Liver, NA
OS↑, TumCG↓, IL6↓, GM-CSF↓, CXCc↓, Macrophages↑, DCells↑, CD4+↑, CD8+↑, IL12↑,
220- MFrot,  MF,    Effect of low frequency magnetic fields on melanoma: tumor inhibition and immune modulation
- in-vitro, Melanoma, B16-F10
OS↑, DCells↑, T-Cell↑, Apoptosis↑, IL1↑, IFN-γ↓, IL10↑, TumCG↓, ROS↑, TumCP↓, TumCCA↑, ChrMod↑, CXCL9↓, CXCL12↓, CD4+↑, CD8+↑,
205- MFrot,  MF,    Intermittent F-actin Perturbations by Magnetic Fields Inhibit Breast Cancer Metastasis
- vitro+vivo, BC, MDA-MB-231
OS↑, F-actin↓, TumCI↓, TumCMig↓, Rho↓, selectivity↑, TumMeta↓,
198- MFrot,  MF,    Biological effects of rotating magnetic field: A review from 1969 to 2021
- Review, Var, NA
AntiCan↑, breath↑, Pain↓, Appetite↑, Strength↑, BowelM↑, TumMeta↓, TumCCA↑, ETC↓, MMP↓, TumCD↑, selectivity↑, ROS↑, Casp3↑, TumCG↓, TumCCA↑, ChrMod↑, TumMeta↓, Imm↑, DCells↑, Akt↓, OS⇅, toxicity↓, QoL↑, hepatoP↑, Pain↓, Weight↑, Strength↑, Sleep↑, IL6↓, CD4+↑, CD8+↑, Ca+2↑, radioP↑, chemoP↑, *BMD↑, *AntiAge↑, *AMPK↑, *P21↓, *P53↓, *mTOR↓, *OS↑, *β-Endo↑, *5HT↓,
217- MFrot,  MF,    Effect of low-frequency rotary magnetic fields on advanced gastric cancer
- in-vivo, GC, HL-60 - in-vivo, GC, SK-HEP-1
OS↑, Pain↓, ChemoSideEff↓, Weight↑, Strength↑, Sleep↑,
772- Mg,    https://pmc.ncbi.nlm.nih.gov/articles/PMC4759402/
- Analysis, NA, NA
OS↑,
5787- NAD,    Nicotinamide and PNC1 govern lifespan extension by calorie restriction in Saccharomyces cerevisiae
- in-vitro, Nor, NA
*CRM↑, *OS↑,
2933- NAD,    Nicotinamide mononucleotide (NMN) as an anti-aging health product – Promises and safety concerns
- Review, Nor, NA - NA, AD, NA - NA, Diabetic, NA - NA, Stroke, NA - NA, LiverDam, NA - NA, Park, NA
*mtDam↓, *BioAv↝, *BioAv↑, *OS↑, *eff↑, *eff↑, *cognitive↑, *DNAdam↓, *SIRT1↑, *cardioP↑, *ROS↓, *Dose↝, *BioAv↑, *hepatoP↑, *eff↑, *BG↓, *creat↓,
2935- NAD,    Long-term NMN treatment increases lifespan and healthspan in mice in a sex dependent manner
- in-vitro, Nor, NA
*GutMicro↑, *OS↑,
5620- NaHCO3,    Tumor acidity: From hallmark of cancer to target of treatment
- Review, Var, NA
e-pH↑, TumCG↓, eff↑, OS↑, eff↑, BioAv↑,
5616- NaHCO3,  DCA,    Bicarbonate and dichloroacetate: Evaluating pH altering therapies in a mouse model for metastatic breast cancer
- vitro+vivo, BC, MDA-MB-231
OS↑, e-pH↑, TumMeta↓, eff↝, TumCG↝,
5606- NaHCO3,    Effects of Alkalization Therapy on Chemotherapy Outcomes in Metastatic or Recurrent Pancreatic Cancer
- Trial, PC, NA
Dose↝, OS↑, eff↑,
5605- NaHCO3,    A nonrandomized cohort and a randomized study of local control of large hepatocarcinoma by targeting intratumoral lactic acidosis
- Trial, HCC, NA
eff↑, Dose↝, other↓, OS↑, toxicity↓, AntiCan↓,
5602- NaHCO3,  immuno,    Immunotherapy Enhancement by Targeting Extracellular Tumor pH in Triple-Negative Breast Cancer Mouse Model
- in-vivo, BC, 4T1
eff↑, TumCG↓, OS↑, e-pH↑, IFN-γ↑, IL2↑, IL12↑, Dose↝, PD-L1↓,
1799- NarG,    Naringenin as potent anticancer phytocompound in breast carcinoma: from mechanistic approach to nanoformulations based therapeutics
- Review, NA, NA
TumCCA↑, BioAv↑, Half-Life∅, TNF-α↓, Casp8↑, BAX↑, Bak↑, EGF↓, mTOR↓, PI3K↓, ERK↓, Akt↓, NF-kB↓, VEGF↓, angioG↓, antiOx↑, EMT↓, OS↑, MAPK↓, ChemoSen↑, MMP9↓, MMP2↓, ROS↑, ROS↑, GSH↓, Casp3↑, ROS↑,
1911- Nos,    Noscapine inhibits tumor growth in TMZ-resistant gliomas
- in-vitro, GBM, NA - in-vivo, GBM, NA
TumCG↓, TumCI↓, OS↑,
1227- OLST,    Anti-Obesity Drug Orlistat Alleviates Western-Diet-Driven Colitis-Associated Colon Cancer via Inhibition of STAT3 and NF-κB-Mediated Signaling
- in-vivo, CRC, NA
OS↑, Inflam↓, TumCG↓, STAT3↓, NF-kB↓, β-catenin/ZEB1↓, Slug↓, XIAP↓, CDK4↓, cycD1/CCND1↓, Bcl-2↓,
1814- Oxy,    Hyperbaric oxygen therapy for malignancy: a review
- Review, Var, NA
ROS↑, SOD↑, OS↑, ChemoSen↑, RadioS↑, BioAv↑,
2051- PB,    Beneficial Effects of Sodium Phenylbutyrate Administration during Infection with Salmonella enterica Serovar Typhimurium
- in-vivo, Inf, NA
*Inf↓, *GutMicro↑, *IL17↑, *Inflam↓, *ER Stress↓, *ROS↓, *OS↑, *Bacteria↓, *Neut↑, *toxicity↓,
2075- PB,  Chemo,    Preliminary Findings on the Use of Targeted Therapy in Combination with Sodium Phenylbutyrate in Colorectal Cancer after Failure of Second-Line Therapy—A Potential Strategy for Improved Survival
- Trial, CRC, NA
OS↑, HDAC↓,
2025- PB,    Complete response of a recurrent, multicentric malignant glioma in a patient treated with phenylbutyrate
- Case Report, GBM, NA
Dose↝, OS↑,
2026- PB,    Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: A dose escalation and pharmacologic study
- Trial, GBM, NA
Dose↝, Dose↑, Dose↝, OS↑, HDAC↓, TumCCA↑, P21↑, other↝, BioAv↑, eff↑,

Showing Research Papers: 151 to 200 of 263
Prev Page 4 of 6 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 263

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress

antiOx↑, 2,   Catalase↑, 2,   GPx↑, 3,   GSH↓, 1,   GSH↑, 1,   GSH/GSSG↓, 1,   H2O2↑, 2,   HO-1↑, 1,   MDA↓, 1,   NRF2↑, 1,   OXPHOS↑, 1,   ROS↑, 14,   SOD↑, 3,   SOD2↑, 1,  

Metal & Cofactor Biology

Ferritin↓, 1,   TfR1/CD71↓, 1,  

Mitochondria & Bioenergetics

EGF↓, 1,   ETC↓, 2,   MMP↓, 4,   MPT↑, 1,   OCR↑, 1,   PGC-1α↑, 1,   PleEff↓, 1,   XIAP↓, 1,  

Core Metabolism/Glycolysis

AMPK↑, 1,   CAIX↑, 1,   ECAR↓, 1,   Glycolysis↓, 1,   lactateProd↑, 1,   PKM2↓, 2,   PPARγ↑, 1,   TCA?, 1,   Warburg↓, 1,  

Cell Death

Akt↓, 3,   Apoptosis↑, 5,   Bak↑, 2,   BAX↑, 3,   Bcl-2↓, 3,   Casp3↑, 5,   Casp8↑, 1,   Casp9↑, 2,   Cyt‑c↑, 2,   JNK↑, 1,   MAPK↓, 1,   MAPK↑, 1,   p27↑, 2,   TumCD↑, 3,  

Transcription & Epigenetics

BowelM↑, 2,   ChrMod↑, 2,   KISS1↑, 1,   other↓, 1,   other↝, 1,  

DNA Damage & Repair

DNAdam↑, 3,   DNArepair↑, 2,   P53↑, 2,   PCNA↓, 1,   γH2AX↑, 1,  

Cell Cycle & Senescence

CDK2↓, 1,   CDK4↓, 4,   CycB/CCNB1↓, 1,   cycD1/CCND1↓, 2,   E2Fs↓, 1,   P21↑, 3,   TumCCA↑, 6,  

Proliferation, Differentiation & Cell State

EMT↓, 2,   ERK↓, 1,   FOXO3↓, 1,   HDAC↓, 2,   IGF-1↓, 1,   IGF-1R↓, 1,   miR-34a↑, 1,   mTOR↓, 2,   P70S6K↓, 1,   PI3K↓, 2,   PTEN↑, 1,   STAT3↓, 3,   TumCG↓, 11,   TumCG↑, 1,   TumCG↝, 1,   VGSC↑, 1,  

Migration

Ca+2↑, 3,   CXCL12↓, 1,   E-cadherin↑, 1,   F-actin↓, 1,   MMP13↓, 1,   MMP2↓, 2,   MMP7↓, 1,   MMP9↓, 3,   Rho↓, 1,   Slug↓, 1,   TGF-β↓, 1,   Treg lymp↓, 1,   TSP-1↑, 1,   TumCI↓, 2,   TumCMig↓, 1,   TumCP↓, 4,   TumMeta↓, 5,   TumMeta↑, 1,   Vim↓, 1,   α-tubulin↓, 1,   β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature

angioG↓, 3,   Hif1a↓, 4,   NO↓, 1,   VEGF↓, 5,  

Barriers & Transport

GLUT1↑, 1,   GLUT3↑, 1,  

Immune & Inflammatory Signaling

CD4+↑, 4,   COX2↓, 2,   CXCc↓, 1,   CXCL9↓, 1,   DCells↑, 3,   FOXP3↓, 1,   GM-CSF↓, 1,   IFN-γ↓, 1,   IFN-γ↑, 1,   IL1↑, 1,   IL10↑, 2,   IL12↑, 2,   IL1β↓, 1,   IL2↑, 1,   IL4↑, 1,   IL6↓, 5,   IL8↓, 1,   Imm↑, 1,   Inflam↓, 1,   Macrophages↑, 1,   NF-kB↓, 4,   NK cell↑, 2,   PD-L1↓, 1,   PGE2↓, 1,   PSA∅, 1,   T-Cell↑, 2,   Th1 response↑, 1,   TNF-α↓, 3,   TNF-α↑, 1,  

Cellular Microenvironment

e-pH↑, 3,  

Hormonal & Nuclear Receptors

GR↑, 1,   RANKL↓, 1,  

Drug Metabolism & Resistance

BioAv↑, 4,   BioAv↝, 1,   ChemoSen↑, 7,   Dose↓, 2,   Dose↑, 3,   Dose↝, 11,   Dose∅, 4,   eff↓, 3,   eff↑, 14,   eff↝, 2,   Half-Life∅, 1,   RadioS↑, 2,   selectivity↑, 7,  

Clinical Biomarkers

AFP↓, 3,   Ferritin↓, 1,   IL6↓, 5,   PD-L1↓, 1,   PSA∅, 1,  

Functional Outcomes

AntiCan↓, 1,   AntiCan↑, 5,   Appetite↑, 2,   breath↑, 2,   chemoP↑, 2,   ChemoSideEff↓, 3,   hepatoP↑, 1,   neuroP↑, 1,   OS↑, 41,   OS⇅, 1,   OS∅, 1,   Pain↓, 5,   QoL↑, 6,   radioP↑, 5,   Remission↑, 2,   Risk↓, 1,   Sleep↑, 2,   Strength↑, 4,   toxicity↓, 4,   TumVol↓, 6,   Weight↑, 2,  

Infection & Microbiome

CD8+↑, 3,  
Total Targets: 179

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress

antiOx↑, 2,   Catalase↑, 1,   GPx↑, 1,   GSH↑, 1,   NFE2L2↓, 1,   ROS↓, 6,   SOD↑, 1,  

Mitochondria & Bioenergetics

mtDam↓, 1,  

Core Metabolism/Glycolysis

AMPK↑, 2,   CRM↑, 1,   SIRT1↑, 1,  

Transcription & Epigenetics

TREM-1↓, 1,  

Protein Folding & ER Stress

ER Stress↓, 1,   ER Stress↑, 1,  

DNA Damage & Repair

DNAdam↓, 1,   P53↓, 1,  

Cell Cycle & Senescence

P21↓, 1,  

Proliferation, Differentiation & Cell State

mTOR↓, 1,  

Migration

Ca+2↑, 1,   β-Endo↑, 1,  

Immune & Inflammatory Signaling

GM-CSF↑, 1,   IL12↓, 1,   IL17↑, 1,   IL23↓, 1,   IL6↓, 1,   Inflam↓, 2,   IP-10/CXCL-10↑, 1,   mPGES-1↓, 1,   Neut↑, 1,   NF-kB↓, 1,   TNF-α↓, 1,  

Synaptic & Neurotransmission

5HT↓, 1,  

Drug Metabolism & Resistance

BioAv↑, 2,   BioAv↝, 1,   Dose↝, 1,   eff↑, 3,   selectivity↑, 1,  

Clinical Biomarkers

BG↓, 1,   BMD↑, 1,   creat↓, 1,   GutMicro↑, 2,   IL6↓, 1,  

Functional Outcomes

AntiAge↑, 2,   cardioP↑, 1,   cognitive↑, 1,   hepatoP↑, 1,   OS↑, 8,   radioP↑, 1,   toxicity↓, 1,   toxicity∅, 2,  

Infection & Microbiome

Bacteria↓, 1,   Inf↓, 1,  
Total Targets: 52

Scientific Paper Hit Count for: OS, overall survival
17 Magnetic Fields
15 Chemotherapy
15 Magnetic Field Rotating
14 Vitamin C (Ascorbic Acid)
13 Hydrogen Gas
10 Radiotherapy/Radiation
9 diet Methionine-Restricted Diet
8 Silver-NanoParticles
8 immunotherapy
8 beta-glucans
7 diet Plant based
7 Selenium
6 Alpha-Lipoic-Acid
6 Curcumin
6 Dichloroacetate
5 HydroxyCitric Acid
5 cetuximab
5 diet FMD Fasting Mimicking Diet
5 Melatonin
5 Bicarbonate(Sodium)
5 Phenylbutyrate
4 Bevacizumab (brand Avastin)
4 EGCG (Epigallocatechin Gallate)
4 capecitabine
4 Phenethyl isothiocyanate
4 Ramucirumab (CYRAMZA)
4 Selenite (Sodium)
3 3-bromopyruvate
3 almonertinib
3 Anti-oxidants
3 Aspirin -acetylsalicylic acid
3 Arsenic trioxide
3 Atorvastatin
3 Gemcitabine (Gemzar)
3 Carvacrol
3 Oxygen, Hyperbaric
3 Exercise
3 diet Short Term Fasting
3 metronomic chemo
3 nicotinamide adenine dinucleotide
3 Sulfasalazine
3 Silymarin (Milk Thistle) silibinin
3 Shikonin
3 Urolithin
2 Lycopene
2 low dose naltrexone
2 Acetyl-l-carnitine
2 Apigenin (mainly Parsley)
2 Ashwagandha(Withaferin A)
2 Bufalin/Huachansu
2 Bifidobacterium
2 Docetaxel
2 Chlorogenic acid
2 Citric Acid
2 Calorie Restriction Mimetics
2 Resveratrol
2 Spermidine
2 Sulforaphane (mainly Broccoli)
2 Disulfiram
2 Orlistat
2 Honokiol
2 itraconazole
2 Juglone
2 Metformin
2 Propolis -bee glue
2 Piperine
2 doxorubicin
2 Quercetin
2 Thymoquinone
2 VitK3,menadione
1 2-DeoxyGlucose
1 Auranofin
1 Astragalus
1 Hyperthermia
1 Akkermansia
1 Baicalein
1 Berberine
1 Brucea javanica
1 Bacopa monnieri
1 Boron
1 Butyrate
1 Caffeine
1 Caffeic Acid Phenethyl Ester (CAPE)
1 Sorafenib (brand name Nexavar)
1 Cannabidiol
1 Celastrol
1 chitosan
1 Chocolate
1 Choline
1 Chrysin
1 Hydroxycinnamic-acid
1 Artemisinin
1 salinomycin
1 Deguelin
1 diet Fermented Foods
1 Bortezomib
1 diet Ketogenic
1 Copper and Cu NanoParticles
1 Emodin
1 Electrical Pulses
1 Garcinol
1 hydroxychloroquine
1 mebendazole
1 nivolumab
1 Magnesium
1 Naringin
1 Noscapine
1 Piperlongumine
1 Radio Frequency
1 Shankhpushpi
1 Iron
1 Salvia miltiorrhiza
1 Tumor Treating Fields
1 Vitamin B1/Thiamine
1 Vitamin K2
1 Xylitol
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:229  State#:%  Dir#:%
wNotes=0 sortOrder:rid,rpid

 

Home Page